Skip to content

Earnings call

Aurobindo Pharma Q4 FY26 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company expects EBITDA margins to sustain and progressively improve to north of 21%, reflecting the scale of its operations, execution capabilities and leveraging the new business lever. Biological CDMO Unit-1 will be commissioned by end of this year, with first 60 KL capacity installation and commissioning guidance unchanged. Pen-G and 6-APA (Lyfius & Qule) projects together made a positive EBITDA contribution in the fourth quarter and year ended March 31, 2026, mainly because of higher operating leverage and better yields. The company is building close to around 75%-85% price erosion for its biosimilar products in Europe. Eugia contributes around 70% of Aurobindo Pharma Limited's overall business.

The numbers management gave

Results

  • Pen-G and 6-APA (Lyfius & Qule) projects together made a positive EBITDA contribution in the fourth quarter and year ended March 31, 2026, mainly because of higher operating leverage and better yields.
    Show source
    S. Subramanian : Yeah, I think if you take Pen -G and 6-APA put together, we have got a positive EBITDA contribution last quarter.
  • European business EBITDA is just in excess of 20% and will move northwards of the same.
    Show source
    So, here EBITDA is just in excess of 20% and we will be moving northwards of same, as stated by our CFO.
  • The company achieved around 11,300 tons capacity in the month of March.
    Show source
    We have achieved in the month of March itself is around 11,300 tons capacity, right.

What it expects ahead

What management expects

  • The company expects EBITDA margins to sustain and progressively improve to north of 21%, reflecting the scale of its operations, execution capabilities and leveraging the new business lever.
    Show source
    We expect EBITDA margins to sustain and progressively improve to north of 21%, reflecting the scale of our operations, execution capabilities and leveraging the new business lever.
  • The company expects the positive EBITDA contribution from Pen-G and 6-APA to continue for the coming years.
    Show source
    We expect this to continue for the coming years, year as a whole.
  • The company expects customer stockpiling requirements in 2028 after PPQ validation batches and customer market filings potentially take place in 2027; a steady stream of revenues from Biological CDMO Unit-1 would begin in 2028. Aurobindo Pharma expects a steady revenue stream from TheraNym unit one beginning in 2028, anticipating customer stockpiling requirements ahead of launch; engineering and validation batches in 2027 will generate revenues; depending on the customer’s stockpiling efforts.
    Show source
    So, a steady stream of revenues, to answer your question, would begin in Unit -1 from 2028.
  • For Aurobindo Pharma's first wave of biosimilar products in the US, the company expects around 65% gross margin as a base even with 75% price erosion; it is not building more than a 60% price erosion in the US.
    Show source
    So, even with a 75% price erosion, we expect to have around 65% gross margin as a base (in the US) and only then we enter into developing these products.
  • The company would like to achieve its target after building in price erosion of around 70%-80% in most markets for its biosimilar products.
    Show source
    So, to answer your question, even after building a very healthy price erosion of around 70%- 80% in most markets, this is what we would like to achieve, Tushar.
  • The company expects Eugia's business split to be 60-40 going forward.
    Show source
    But going forward, we expect that to be a 60-40.
Show 4 more statements

What management expects

  • The company is trying to achieve double-digit growth and, considering the current geopolitical situations, has taken it a bit conservatively but is confident it will be minimum double digit.
    Show source
    And, of course, considering the current geopolitical situations, we have taken it bit conservatively but we are confident it will be minimum double digit.
  • Omalizumab and Denosumab will enter the filing phase with European Medicines Agency, Health Canada and the FDA this year.
    Show source
    So, revenue recognition will follow as those products will move through distribution channels into procurement, etc. In terms of what we are doing, we have Omalizumab and Denosumab, as I have talked about in the last quarter, that will be entering the filing phase with European Medicines Agency, Health Canada and the FDA this year.
  • The company plans to file Bevacizumab in the US; it is already approved with Health Canada and MHRA and is currently under review with European Medicines Agency.
    Show source
    We also plan to file that in the US.
  • The company expects the Speciality injectables business, excluding Lenalidomide, to achieve the same double-digit growth going forward.
    Show source
    It is the other than the Lenalidomide, it is 13% and I feel like the same double-digit growth is expected going forward.

What it is building and selling

Projects and capacity

  • Biological CDMO Unit-1 will be commissioned by end of this year, with first 60 KL capacity installation and commissioning guidance unchanged.
    Show source
    About the CDMO unit, the Unit-1 will be commissioned by end of this year.
  • The company expects to close commissioning of the greenfield drug substance manufacturing facility under the recently signed Product Schedule three in 2029.
    Show source
    We expect to close the commissioning of the facility in 2029.
  • Product Schedule one, Product Schedule two and Product Schedule three together amount to about 120,000 litres of drug substance manufacturing mammalian cell culture capacities.
    Show source
    Now, if you look at my product Schedule one, product Schedule two and product Schedule three that we have disclosed to the exchanges, the total drug substance manufacturing scales amount to about 120,000 litres of mammalian cell culture capacities.

Demand and pricing

  • The company is building close to around 75%-85% price erosion for its biosimilar products in Europe.
    Show source
    In Europe, we are building close to around 75%-85% price erosion.
  • The company says pricing is good in some growth markets for its biosimilar products.
    Show source
    In growth markets, actually the pricing is good in some of the growth markets.

Segments

  • Eugia contributes around 70% of Aurobindo Pharma Limited's overall business.
    Show source
    30% comes from other than US.
Show 3 more statements

Deals and partners

  • The company has initiated supplies of biosimilars to certain territories in the EU, is servicing a tender in LATAM, and the STADA agreement will start to fructify from the end of this year.
    Show source
    So, supplies have been initiated to certain territories in the EU, tender is being serviced in LATAM and the STADA agreement will start to fructify from the end of this year.
  • The company has signed three product schedules, each for one product; technology transfer of one new biological entity is happening, and that product is already commercial.
    Show source
    So, we signed about 3 product schedules, which means that we signed for 3 products.
  • Second product schedule is for a commercial biological entity; one of the two commercial products is early commercial and the other is relatively established.
    Show source
    One of them is an early commercial product , the other one is a relatively established product.

Risks, rules and outside factors

Outside factors

  • The company says solvent prices have gone by 2.5X as raw material prices are going up.
    Show source
    Raw material prices are going up and solvent prices have gone by 2.5X.
  • The company says freight cost went significantly high in March and continued high in April and May, solvent prices went by 2.7X, and other raw material prices are also going.
    Show source
    Freight cost actually has gone significantly high in the last month in March and continuing in April and May, solvent prices have gone by 2.7X, raw material, other raw material prices are also going.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Damayanti Kerai: So, any indication on the growth rate? Say, we can comfortably target for double-digit growth, say low double digit to mid-teens or any number you would like to share? 7 Aurobindo Pharma Limited 22 May 2026 V. Muralidharan: So, we are definitely trying to achieve the double digit growth.

    Answer, v muralidharan

    And, of course, considering the current geopolitical situations, we have taken it bit conservatively but we are confident it will be minimum double digit.

  2. Question

    Charul Agarwal: Hi. Thank you, Sir, for taking my question. My first question is on the CDMO unit, Biological CDMO unit. When do we start seeing it commercializing and when do we expect the first revenue from the segment?

    Answer, satakarni makkapati

    Satakarni Makkapati: Hi. About the CDMO unit, the Unit-1 will be commissioned by end of this year. So, my guidance around the first 60 KL capacity installation and commissioning remains the same. With the PPQ batches, which are the validation batches Scheduled in 2027, and the filings in the markets by the customer also slated (potentially) to happen in 2027, we expect some stockpiling requirements from the customer in 2028. So, a steady stream of revenues, to answer your question, would begin in Unit -1 from 2028. With respect to the recent Product Schedule three that I have signed , and we have informed the exchanges about, that is a greenfield drug substance manufacturing facility. We expect to close the commissioning of the facility in 2029.

    Answer, satakarni makkapati

    Two years from then, 2031 , would be the start of revenues from Unit-2. So, in a nutshell, between Unit-1 and Unit-2, you would expect the revenues to kick in from 2031. But Unit-1 will have a head start from 2028.

  3. Question

    Charul Agarwal: Thank you, Sir, for this. My next question is again on the Pen -G. So, when do we start the external sales from the unit? While it has been contributing to the internal supply, but when do the external supply start?

    Answer, s subramanian

    S. Subramanian: The external supply has already been happened in the last quarter. We have sold more than ₹100 crores worth of material in the last quarter, both Pen -G as well as 6-APA to the outside market. We have also already informed all the customers that they can pick up the material because some stocks are there in the market ear lier because of the high imports in the Q3 of this year, FY26, the offtake was very low but we expect the offtake will take up strongly in the coming days, coming weeks.

  4. Question

    Surya Patra: Yeah, Thank you for this opportunity, Sir. My first question is on the European business. So, congrats for the €1 billion milestone mark that you have achieved. But if you can update, what is the EBITDA for that? 8 Aurobindo Pharma Limited 22 May 2026 V. Muralidharan: Yes.

    Answer, v muralidharan

    So, here EBITDA is just in excess of 20% and we will be moving northwards of same, as stated by our CFO. Rahul: Hello. Yeah, hi, Sir. Thanks for taking my question. Sir, I guess your $2 billion revenue guidance for the US business factors in Lannett as well, which alone should contribute $300 million incremental sales. And with that, you should get to $1.9-$1.95 billion. So, this guidance is essentially driven by Lannett.

  5. Question

    Swami Iyer: So, I will take this question, okay.

    Answer, s subramanian

    S. Subramanian: Yeah-yeah. Swami Iyer: So, first of all, Rahul, Lannett is probably going to be there for two quarters in the current fiscal. So, this is going to be half of Lannett. So, that is number one and that is also subject of approval, which we expect, which we are confident. So, that is one. And then we are looking at some business opportunities. And those opportunities, we believe that we are in a good position now.

    Answer, s subramanian

    So, you know, timing wise, I cannot tell you for certain, but we are heading towards a $2 billion goal and Lannett is part of it. Maybe in the next 1-2 years, definitely we are getting there. And you are already aware that Lannett is about $300 million. Obviously, we should be heading towards that $2 billion mark in the near future. That is all I can say. Maybe in 1-year plus, maybe in 1-year, if we are lucky. Again, it depends on the FTC approvals and some of the business development deals getting operational.

  6. Question

    Nitin Agarwal: Hi, Sir. Thank you for taking the question. Sir, on the biosimilar business, you highlighted, FY30 vision, 2030 vision, for the biosimilar business. If you can probably just articulate in terms of, what are we looking at, especially in terms of number of products being marketed, commercialized by them and what kind of geographical spread we are looking at by 2030 for the biosimilar business?

    Answer, satakarni makkapati

    Satakarni Makkapati: Hey, Nitin. It is a good question. We are right now in the early innings of launch, since a quarter I suppose, with biosimilars, Nitin. So, supplies have been initiated to certain territories in the EU, tender is being serviced in LATAM and the STADA agreement will start to fructify from the end of this year. So, revenue recognition will follow as those products will move through distribution channels into procurement, etc. In terms of what we are doing, we have Omalizumab and Denosumab, as I have talked about in the last quarter, that will be entering the filing phase with European Medicines Agency, Health Canada and the FDA this year. Additionally, I have also provided guidance in Q2 that we plan to file Bevacizumab, which is already approved with Health Canada, approved with MHRA, and currently under review with European Medicines Agency. We also plan to file that in the US.

    Answer, satakarni makkapati

    So, 2026 will be a year where we wanted to execute the US filings, the three filings in the US, at least two, but three filings in the US. So, what it does to the business, if you look at 2030, is that the first wave of products that have been or are being commercialized now, plus the three more products that will be approved in Europe, is a clear base. So, you have about seven products in Europe, emerging markets and the growth markets. As I have provided guidance in the Earnings presentation, I am also stitching partnerships in territories where we are not directly present. So, for all these to strategically fructify would take a year or two. But with the 7-8 product base model in Europe approved and in growth markets, a potential 3 products approval by 2028, 2029 or 2030, even with a slight US FDA setback if there is any. By 2030, we are looking at biosimilars business having 7-8 products in Europe and growth markets, plus potentially 2-3 products in the US.

    Answer, satakarni makkapati

    I would not give any guidance, specific revenue figures at this stage, but the commercial momentum is real and is building and I expect by 2030 with the 7 plus 3 products that I am planning in the US, biosimilars business will have an inflection point, as I've also guided all through in the last year and the last quarter as well. Does that answer your question?

  7. Question

    Nitin Agarwal: I was saying, in the first wave of launches that we have, the fact that we are coming much behind the competition, in Europe and in emerging markets, do you still see an ability for us to make reasonable revenues on these products? Is the opportunity still relevant for us in the first wave of launches? 10 Aurobindo Pharma Limited 22 May 2026 Satakarni Makkapati: In the first wave of launches, the opportunity is relevant to the extent the aspiration is.

    Answer, satakarni makkapati

    So, we are not looking at a 15%-20% market share in those territories. With the right cost of goods, we still believe there is enough opportunity for everyone. Also, if you look at the nature and dynamics of the biosimilar business now, even if you look at products that are going off the patent cliff in 2032, you have about 10-11 players who are already doing clinical trials or developing them. So, if you want to sustain in this business, you need to really create a COGS model that will allow you to position yourselves in the market. What is also important is creating a basket of products in oncology and immunology. Right now, the choice of products that we have made, I'll give an example of pegylated filgrastim, which is a long-acting filgrastim that is expected to increase the neutrophil count in cancer patients who suffer from a condition called neutropenia. So, there is no follow-on drug for this product.

    Answer, satakarni makkapati

    So, what we are looking at from the first wave, Nitin, is products that have a longer life cycle. So, Pegfilgrastim, even now is a potentially $3.5-$4 billion market (global) and I expect it to continue to grow. And in US, I think there are about 4 -5 or 5 players there. I am sure if you're looking at the $50 - $60 million dollar revenues and not looking at taking away 20% -25% of the market share, you are still in the game. In that sense, it's a very calculated move from us to pick products that have a longer life cycle. Another example is, Trastuzumab where we launched the 150 and 420 mg but the real game with Trastuzumab is the subcutaneous that we are developing. The patent goes off in 2028- 29.

    Answer, satakarni makkapati

    So, you should look at it from a strategic perspective of how we are positioning the products that will advance our aspirations in this space. Our COGS, I think, will continue to sustain us but if you are saying, ‘Will I be picking up a 20%-25% market share?’, absolutely not. And that's not the aspiration at all.

  8. Question

    Nitin Agarwal: Thank you, Sir. That helps. And, secondly, at what point in time do you start to be part of the first wave of launches going forward?

    Answer, satakarni makkapati

    Satakarni Makkapati: So, it's a trick question. Omalizumab, I think we will be in the first wave. If you say first wave, is 3-4 players right now. With Omalizumab, there are 3 serious players. Celltrion has already made the move. It's a potential $4 billion market. There are 2 other players there and then there is us.

    Answer, satakarni makkapati

    We expect Omalizumab to be a $2 to $2.2 billion product even after the biosimilar competition kicks in. So, I think that would be the first wave and we have the capacities to sustain the supply chain in markets like US for Omalizumab. With the next wave of products, we are trying to green light the clinical studies for the next wave of products from that goes off patent cliff from 2030-31 onwards and we may be in the first wave. But first wave is becoming very subjective these days, Nitin. If I pick a product from 2034, like Atezolizumab, there are 9 players who are already developing. So, we really see how the dynamics play out. It's quite intuitive and subjective to answer the question but I hope you got the clarity of the point that I'm trying to say.

    Answer, satakarni makkapati

    11 Aurobindo Pharma Limited 22 May 2026 Nitin Agarwal: Yeah, that's very helpful.

  9. Question

    Also, if I can squeeze in one last one. Sir, on CDMO, how should we think about CDMO? Our CDMO strategy is all about these 2 MSD projects or do you see opportunities to significantly go beyond that? And at what point can that happen?

    Answer, satakarni makkapati

    Satakarni Makkapati: It's a good question. See, the scales at which we are attempting to become a CMO is a key differentiator in India, right. Now, if you look at my product Schedule one, product Schedule two and product Schedule three that we have disclosed to the exchanges, the total drug substance manufacturing scales amount to about 120,000 litres of mammalian cell culture capacities. Now, that's by far the largest CMO space in the country and which will put us into the lower rank bracket of the largest CMOs in the world. For example, Lonza has about 570,000 litres , Samsung has around 600,000 litres. So , having 120,000 litres is a statement ; statement and intent that we are here to stay. Now, why do I build a business model around one anchor customer?

    Answer, satakarni makkapati

    Because India traditionally did not have contract manufacturing organizations in the new biological space. It requires deep competence, infrastructure building and the nurturing of human reso urces capabilities like no other. And that's the reason why I wanted to derisk the ramp . And by mean of derisking the ramp, I wanted to get an anchor customer like MS D, get a contract with them for about 10 years and see how credibly I can build the busine ss for the next 5 years. But to answer your question, does TheraNym and does I and Aurobindo and the board want us to be a single customer CMO after 2032? No. The vision statement for 2032, which I presented to my board yesterday also, is that we wanted to be a multi -modality, mul ti- customer, contract development and contract manufacturing organization. Right now, we are a CMO, make no mistake about it.

    Answer, satakarni makkapati

    We are not a CDMO right now. We wanted to be a CMO but we wanted to backward integrate by 2032 to become a contract development organization. So, this is not going to be a one customer business. But for the first 5 years, until I build credibility around an anchor and service the anchor and create a space that we are also a credible CMO coming out and can service the new biological entities and become part of the global supply chain, yes, we would like to stay with MSD and learn through the curve. But the long-term aspiration and ambition is to become a multi-modality, multi-customer CDMO and transition from a CMO to CDMO. Does that answer your question?

  10. Question

    Tushar Manudhane: And, Sir, this is after building what kind of…Particularly in biosimilars, we've witnessed a sizable price erosion post competition coming in. So, this kind of gross margin, this is the manufacturing skillset which we have got. What kind of price erosion we try to build for these set of products ? We understand like a post such kind of price erosion, the gross margin is 65 %-70%.

    Answer, satakarni makkapati

    Satakarni Makkapati: So, for the first wave of products we have already built in the price erosion to a great extent. So, even with a 75% price erosion, we expect to have around 65% gross margin as a base (in the US) and only then we enter into developing these products. In the US, we are not building more than a 60% price erosion. In Europe, we are building close to around 75%-85% price erosion. We have seen that happen in chronic segment in Europe. In growth markets, actually the pricing is good in some of the growth markets. So, to answer your question, even after building a very healthy price erosion of around 70%- 80% in most markets, this is what we would like to achieve, Tushar.

Show 17 more questions
  1. Question

    Tushar Manudhane: That's pretty interesting, Sir. And just to sort of complete this loop, in chemical synthesis probably the scale does help in getting the EBITDA margin but with respect to biosimilars, just trying to understand, you know, despite such kind of price erosion we able to achieve 65%-70% gross margin. So, if you could just help with that missing link compared to, say, a chemical synthesis process ?

    Answer, satakarni makkapati

    Satakarni Makkapati: It's a very interesting question from a sense that you should always look at, in biologics you should always look at yield versus COGS as a function of also capacities, okay, which is true even in small molecules. But in biologics, when I plot yield and 13 Aurobindo Pharma Limited 22 May 2026 capacities on the primary y-axis and the secondary y-axis and COGS on the horizontal axis, you see the tapering of the COGS pretty early. So, depending on your capacities. If my capacities are around 5,000-litre scale and my yield is around 4 gram per litre, then the incremental improvements, even after increasing the scale, are going to be very, very minimal in terms of cost of goods. So, factoring all these models, we still think if you have built your capacities right, if you have positioned your titres or the yields around 4-6 gram per litre because after which the downstream costs will start to trade off any benefits that you will get from the cell culture yields. So, around 4-6 gram per litre and a capacity of around 2,500 to 5,000 litre bioreactors, you should have a cost competitiveness for most monoclonal antibodies that are at 100 mg- 400 mg filling doses. I think 60%-65% should be very straightforward in biologics (in the US), even with the price erosion of around 70% that you witness.

    Answer, satakarni makkapati

    But the trick there is, do companies have the yields of around 4-6 gram per litre at the right quality? Do companies have the right capacities for the products they are putting in at 4-6 gram per litre? And if either of these on the primary and secondary y-axis do not meet together, then you are looking at numbers and margins that can be significantly less because their COGS is going to be higher.

  2. Question

    Tushar Manudhane: Yes.

    Answer, satakarni makkapati

    Satakarni Makkapati: About $450 million is the overall investment including CapEx and OpEx that was done in biosimilars and that had resulted from 2018 July to now, including the two COVID years, into 4 European approvals, 2 Health Canada approvals and 3 more product filings now; the fastest in the peer group that you can look at. And I am confident that we will continue the momentum.

  3. Question

    Tushar Manudhane: So, $150-$175 million is the over and above?

    Answer, satakarni makkapati

    Satakarni Makkapati: No, this is a CMO, okay. The CMO is going to be about $175 million in the greenfield facility.

  4. Question

    Kunal Dhamesha: Okay. And Euro? INR depreciation against Euro would be addition to that, right?

    Answer, s subramanian

    S. Subramanian: Yeah, Euro is very little, okay, because already Euro has achieved the peak. Earlier it used to be around 1.03 [EUR/USD], now it is hovering between 1.16-1.17. So, may not have a big significant one on Euro but EBITDA on dollar-rupee transaction, we will get around ₹100 [Crores].

  5. Question

    Kunal Dhamesha: And, Sir, the 21% EBITDA margin guidance for FY27, does it bake in this positive impact of the INR depreciation?

    Answer, s subramanian

    S. Subramanian: Don't look into that, no. Because, see, nothing comes free. When rupee is depreciating, why is it depreciating? Raw material prices are going up and solvent prices have gone by 2.5X. Don't make it only rupee depreciation going to translate. It is a combination of all these we have to see. Freight cost actually has gone significantly high in the last month in March and continuing in April and May, solvent prices have gone by 2.7X, raw material, other raw material prices are also going. So, you have to look at it in a holistic manner rather than seeing it in a very limited manner.

  6. Question

    Kunal Dhamesha: Okay. So, maybe, you know, 21% bakes in the net impact of all these positives and negatives ?

    Answer, s subramanian

    S. Subramanian: All these factors. All the pluses, minuses, etc. , we are working.

  7. Question

    Kunal Dhamesha: Okay. And second question on the Pen -G, we said that the 10,000 ton is the output. You know, we are going to reach that kind of level now with an 80% cap utilization. To me, a very basic math kind of points to 12,500 tons of total capacity versus our total capacity is 15,000. So, is it fair to say in terms of yields, you know, there could be some more improvement going forward?

    Answer, s subramanian

    S. Subramanian: No, no, not like that, Kunal. I said it is above 10,000 tons. We have achieved in the month of March itself is around 11,300 tons capacity, right. 15 Aurobindo Pharma Limited 22 May 2026 Kunal Dhamesha: Okay.

  8. Question

    Okay.

    Answer, s subramanian

    S. Subramanian: April, we made it around 10,800. So, the capacity is not 15,000 or not like that. We have 17 fermenters; we can run any number of fermenters I want and accordingly the capacity is achieved. So, we have to ensure that the inventory buildup is not happening, working capital is not locked in. And at the same time, we need to achieve the right yields, etc. That is what the team is working on.

  9. Question

    Kunal Dhamesha: Yes. Yes. Yes. And lastly, for Dr. Satakarni, on the TheraNym contracts. Sir, can you suggest how many products have we got right now from Merck? And are these in development stage or already commercialized? If they are already commercialized, are they in the early part of their product lifecycle, late part of product lifecycle? Any color would be helpful.

    Answer, satakarni makkapati

    Satakarni Makkapati: Kunal, product Schedule 1 is for 1 product, product Schedule 2 is for 1 product. In the nutshell, each product schedule is for 1 product. So, we signed about 3 product schedules, which means that we signed for 3 products. Right now, technology transfer of 1 product, a new biological entity is happening. This is a product that is already commercial. The second product schedule also is a commercial biological entity. One of them is an early commercial product , the other one is a relatively established product.

    Answer, satakarni makkapati

    I cannot give more details about the sponsors' products but we will be into the commercial global supply chain right from Day 1 after receiving the regulatory approvals. And that is the business model of TheraNym. Right from day 1, once you have the regulatory approvals, the product that we are going to manufacture at TheraNym is going to be used by MS D into their global supply chain for the patients in the territories and the markets they would like to supply the product to. Does that answer your question?

  10. Question

    Kunal Dhamesha: Sure.

    Answer, satakarni makkapati

    Satakarni Makkapati: So, there is no development product at this stage. Both are commercial assets.

  11. Question

    Kunal Dhamesha: Okay. And earlier we had said that these supplies would initially be used for emerging markets and then in Europe and then in US. Is that the correct way of understanding? 16 Aurobindo Pharma Limited 22 May 2026 Satakarni Makkapati: That's correct.

    Answer, satakarni makkapati

    That's correct because capability building and GMP compliance takes time. Initially, I expect MSD to file it in emerging markets followed by Europe. And potentially at some point, maybe they would say they would also like us to become part of the supply chain for the US. But right now, I would keep the aspiration to emerging markets and Europe. Kunal Dhamesha: Thank you and all the best, Sir.

  12. Question

    Shyam Srinivasan: Good morning. Thank you for taking my question. Just the first one on the Speciality injectables. I think in the opening remarks it was said $513 million has been the total revenue for the year and I think 13% growth. Sir, if you could just double click there, you know, and how should we look at the outlook for it in FY27?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Yeah. You heard it right from Subbu. It is the other than the Lenalidomide, it is 13% and I feel like the same double-digit growth is expected going forward.

  13. Question

    Shyam Srinivasan: But Yugandhar, there is some Revlimid already in 2026, right? So 513 million includes Revlimid. So you are excluding it and telling us it's whatever double-digit growth. Sorry, can you just can you just help us what the base number would be?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: It’s actually like the base number would be around 480 plus. So like we expect a similar double-digit growth because this year of ‘27 onwards, we will not have the Revlimid. So we expect the base business to continue to grow in double digits.

  14. Question

    Shyam Srinivasan: And any interesting launches coming up in this segment, Yugandhar? Anything to call out?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Yeah, it is at this juncture. It is too early for me to comment, Shyam, because of Eugia III. So, there are some interesting launches from other plants, but we are at this juncture keeping ourselves on watch for all the regulatory approvals for the plants so that in next quarter I can give more colour.

  15. Question

    Shyam Srinivasan: Understood. Thank you. My just last question to Dr. Satakarni. Dr. Satakarni, now we have all your large cap peers, like large peers, all talking about Biosimilar. So, Sun through the Organon deal has got it, Dr. Reddy's , Lupin have got it. I'm not asking for names, but I'm just saying, is this going to be an interesting phase where we have to now slug it out with some of your other peers? And is there something you will do differently to kind of get your whatever rightful share?

    Answer, satakarni makkapati

    Satakarni Makkapati: It's interesting, Shyam, I mean, how can I, how can I comment on the slugfest that is going to unfold in the Biosimilar space, it's already happening in Europe. One of the previous questions from Nitin, I told the market dynamics is going to be so interes ting, the price erosion is going to be so interesting. The competition. Any product that you pick, there are about 10 to 11 players. What is important is to ensure that you have a basket of products that you can go to into the market, create a brand name, as long as they are continuing to be brands like in Canada and US, and make sure that your COG S setting is good enough to still give you a reasonable margin. I don't think I can do anything differently than what I have done, the speed and agility with which we have looked at the last 7 -8 years in building these capabilities, I would like to sustain the momentum. And if that happens, I think we are in a good spa ce right now.

    Answer, satakarni makkapati

    The most important aspect for CuraTeQ is the execution of the US filings and can we execute it right first time? And if we do, I think we will be having a very different conversation.

  16. Question

    Jigar Valia: I'm sorry. So firstly, congratulations on the decent set of numbers under the circumstances with API prices and freights, and I think your growth markets, etc., I think all helped API. So one is with regards to China and India. So , has China break-even helped in margins this time? And as far as India, I think it is about 76 crores a quarter. So , will this Khandelwal acquisition kind of… how much would that kind of contribute to the run -rate?

    Answer, s subramanian

    S. Subramanian: So, in terms of the China, as I said, last quarter we had a loss of around 7 million… last year, I'm sorry, last year. But certainly, this year will not only break -even, will contribute significantly. At least we are working to achieve a low double -digit EBITDA margin for the year. That is what we are trying to do there. In terms of the Khandelwal Labs, etc., it's a very decent acquisition and it is contributing to the EBITDA margin. And we expect overall; the entire domestic formulation business will grow in double-digit during this year. 18 Aurobindo Pharma Limited 22 May 2026 Jigar Valia: Got it.

  17. Question

    Tarang Agrawal: Got it. And last on Eugia, if you could give us a split for FY26 and FY25 between US and ex-US. 21 Aurobindo Pharma Limited 22 May 2026 Yugandhar Puvvala: Yeah, it is anyway, because we don't give separate numbers, but it still contributes around 70% of the overall business.

    Answer, yugandhar puvvala

    30% comes from other than US. But going forward, we expect that to be a 60-40.

Questions about this call

When was the Aurobindo Pharma Q4 FY26 earnings call transcript filed?
Aurobindo Pharma filed the transcript with the exchange on 27 May 2026. This page is built from that transcript.
What does this page list?
24 statements from the transcript across 7 topics, 16 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 27 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Aurobindo Pharma Q4 FY26 concall: what the company said · DalalOS